Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way.
Otávio Augusto ChavesCarolina Q SacramentoNatalia Fintelman-RodriguesJairo Ramos TemerozoFilipe Santos Pereira-DutraDaniella M MizuriniRobson Q MonteiroLeonardo VazquezPatricia T BozzaHugo Caire Castro-Faria-NetoThiago Moreno L SouzaPublished in: Journal of molecular cell biology (2022)